ADVERTISEMENT

Clozapine for schizophrenia: Life-threatening or life-saving treatment?

Current Psychiatry. 2009 December;08(12):56-63
Author and Disclosure Information

Clozapine, despite its side effect burden, may be the most effective and have the lowest mortality risk among all available antipsychotics

16

Table

Common adverse effects of clozapine

Adverse effectFrequency*
Hypersalivation31% to 48%
Drowsiness/sedation/somnolence39% to 46%
Weight increase31%
Tachycardia25%
Dizziness/vertigo19% to 27%
Constipation14% to 25%
Seizures5% (can be higher with doses approaching 900 mg/d); slow titration needed
*Pooled data from clinical trials reporting percentage of patients taking clozapine who experienced adverse effects
Source: Prescribing information for Clozaril® brand clozapine tablets. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed October 27, 2009
Myocarditis may be difficult to diagnose, and commonly used tests have limited sensitivity. A symptom questionnaire—such as described by Annamraju et al17 —may help with earlier recognition of this potentially fatal complication, particularly during the first weeks of clozapine treatment.

Adjunctive treatments. Patients with a low baseline white blood cell count (WBC) and/or absolute neutrophil count (ANC) may benefit from adjunctive lithium treatment to increase their WBC, as demonstrated in case reports.18

When no other alternatives were clinically feasible, chronic treatment with granulocyte colony-stimulating factor (filgrastim) has been used successfully for some patients whose clozapine course was interrupted because of a low WBC and/or ANC.19

Related resources

Clozapine registries (by manufacturer):
Drug brand names
  • Chlorpromazine • Thorazine
  • Clozapine • Clozaril, FazaClo
  • Filgrastim • Neupogen
  • Haloperidol • Haldol
  • Lithium • Lithobid, others
  • Olanzapine • Zyprexa
  • Perphenazine • Trilafon
  • Quetiapine • Seroquel
  • Risperidone • Risperdal
  • Thioridazine • Mellaril
  • Ziprasidone • Geodon
Disclosures

Dr. Citrome is a consultant for, has received honoraria from, or has conducted clinical research supported by Abbott Laboratories, AstraZeneca, Avanir Pharmaceuticals, Azur Pharma Inc., Barr Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Forest Research Institute, GlaxoSmithKline, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Pfizer Inc., Schering-Plough Corporation, and Vanda Pharmaceuticals. No writing assistance or external financial support was utilized in the preparation of this review article.